Excellergy revealed its $70 Million Series A financing, which focuses on strengthening its portfolio of first-in-class allergic Effector Cell Response Inhibitors (ECRIs). The company was seeded in 2021 by Red Tree Venture Capital and built on scientific advances in the structural binding of IgE to its receptor from Stanford University and the University of Bern.¹ Excellergy developed its pipeline of trifunctional ECRIs through its well-established IgE pharmacology, focusing on redefining the standard of care across various allergic diseases, with plans to move their lead asset into the clinic in early 2026.¹

How does Excellergy’s class of ECRIs employ a trifunctional mechanism of action?

• Rapidly remove IgE bound to FceRI on mast cells and basophils without triggering activation of these cells
• Deliver potent, high-affinity neutralization of free IgE
• Accelerate downregulation of FceRI expression.

These three functions act synchronously and hold the potential to initiate faster onset along with offering improved control over allergies in broader patient populations compared to previously approved treatments.¹

Supporting data confirming the mechanism of ECRIs was published earlier in October this year, in the Journal of Allergy and Clinical Immunology, an official publication of the American Academy of Allergy, Asthma, and Immunology (AAAAI).¹ The data provides sufficient evidence showing that receptor-bound IgE are able to be actively removed from mast cells and basophils without triggering their activation.¹ This discovery assisted in establishing the scientific foundation for this new therapeutic class.

“The pre-clinical data supporting Excellergy’s trifunctional ECRIs are compelling, showing a broad-spectrum attack on the IgE axis that goes well beyond conventional anti-IgE approaches,” said Leonard B. Bacharier, M.D., Janie Robinson and John Moore Lee chair in pediatrics and professor of pediatrics, allergy/immunology/pulmonary medicine at Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center. “Unlike therapies that only bind free IgE, ECRIs act across multiple pathways, directly disarming effector cells through a novel mechanism distinct from classic anti-IgEs. These findings provide strong support for advancing into Phase 1 and highlight the potential to impact multiple allergic diseases.”

Who is leading Excellergy?

Veteran biotech executive Todd Zavodnick serves as chief executive officer of Excellergy. Zavodnick has upwards of 25 years of experience in global leadership in drug development, commercialization, and corporate scale-ups.¹ Co-founder and chief scientific officer, Geoffrey Harris,DVM, PhD, along with chief medical officer Philip M. Brown, MD, JD, joins Zavodnick.

“We are not here to refine the status quo. We are here to build a portfolio of category-defining assets that will advance and reset the standard of care in allergy,” said Todd Zavodnick, president and chief executive officer at Excellergy. “By directly removing IgE bound to the receptor, our first-in-class trifunctional ECRIs are engineered to shut down the allergic response at its source, something current therapies cannot achieve. As each program represents a true pipeline-in-a-product, we are unlocking a multi-billion-dollar opportunity across a broad range of allergic conditions, while delivering the potential to improve the lives of millions of patients worldwide.”

Red Tree Venture Capital’s statement

“Excellergy’s potential is extraordinary,” said Heath Lukatch, Ph.D., founder & managing partner at Red Tree Venture Capital. “By leveraging well-understood IgE biology in a novel way, the company is both differentiated and advancing innovation from a pathway that clinicians and scientists already trust. This foundation makes its portfolio of first-in-class trifunctional ECRIs uniquely positioned to capture substantial market value and make a lasting impact on patients’ wellbeing in the allergy space.”

Sources

1. Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control Excellergy October 13, 2025 https://www.globenewswire.com/news-release/2025/10/13/3165481/0/en/Excellergy-Debuts-with-70-Million-Series-A-Financing-to-Advance-First-in-Class-Portfolio-of-Trifunctional-Effector-Cell-Response-Inhibitors-ECRIs-for-Complete-Allergic-Control.html